Status:
UNKNOWN
FDG - PET / MRI in Patients With Rectal Cancer
Lead Sponsor:
Region Västerbotten
Conditions:
Rectal Cancer
Lymph Node Metastases
Eligibility:
All Genders
18+ years
Brief Summary
The combination of FDG-PET/CT and MRI at staging of rectal cancer in diagnosis is currently very little studied. The investigator have a unique opportunity to study this. Hypothetically, with PET/MR a...
Detailed Description
Today, there is a variety of treatment options in diagnosed rectal cancer. The standard treatment is surgery with removal of the tumour including surrounding fat and lymph nodes in a package. Prior to...
Eligibility Criteria
Inclusion
- \* verified rectal cancer of intermediate or high risk type, scheduled for surgery (non-acute surgery)
Exclusion
- kidney dysfunction
- any other contraindications for contrast agents or examination with MRi or FDG-PET/CT
Key Trial Info
Start Date :
December 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03846882
Start Date
December 1 2015
End Date
December 31 2023
Last Update
February 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radology
Umeå, Sweden